Last reviewed · How we verify
OK-101
At a glance
| Generic name | OK-101 |
|---|---|
| Sponsor | Okyo Pharma Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- The Study Assessing the Safety and Efficacy of OK-101 Treatment in Subjects With Neuropathic Corneal Pain (PHASE2)
- The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OK-101 CI brief — competitive landscape report
- OK-101 updates RSS · CI watch RSS
- Okyo Pharma Ltd portfolio CI